Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial

Wei, Hao; Sun, Yu; Xie, Liang-Liang; Jia, Yuming; He, Jun; Deng, Xiaofei; Huang, Wei; Zhu, Jiang

doi:10.1089/jicm.2022.0672

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, the acute (the first day of chemotherapy) and the delayed (day 2–5) CINV phases have been used as critical research phase in most clinical studies (Wu et al 2018 ; Schwartzberg et al 2018 ; Hashimoto et al 2020 ; Zhang et al 2018 ). CINV occurred beyond the risk phase was investigated in our previous studies (Sun et al 2021 ; Li et al 2022 , 2018 ; Wei et al 2023 ), and the incidence of CINV occurred during 120-168 h was about 26% according to the recent Japanese data (Hata et al 2022 ). Researchers tried the novel definition of CINV phase for multi-day cisplatin chemotherapy: the current study team defined the acute phase as day1–3, the delayed phase as day4 -day7, and the period beyond the risk phase as from day 8 to 21 in our prior studies about 3-day cisplatin (Li et al 2022 ; Wei et al 2023 ).…”

Section: Discussionmentioning

confidence: 99%

“…CINV occurred beyond the risk phase was investigated in our previous studies (Sun et al 2021 ; Li et al 2022 , 2018 ; Wei et al 2023 ), and the incidence of CINV occurred during 120-168 h was about 26% according to the recent Japanese data (Hata et al 2022 ). Researchers tried the novel definition of CINV phase for multi-day cisplatin chemotherapy: the current study team defined the acute phase as day1–3, the delayed phase as day4 -day7, and the period beyond the risk phase as from day 8 to 21 in our prior studies about 3-day cisplatin (Li et al 2022 ; Wei et al 2023 ). Another Chinese trial focused on 3-day cisplatin regimen defined the acute phase as day1-day3, the delayed phase as day4-day8 (Zhao et al 2023 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting

Li,

Wan,

Yang

et al. 2024

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose Neurokinin 1 receptor antagonists included prophylactic treatment was recommended for patients who receive one-day cisplatin chemotherapy. It is unclear whether the prolonged administration of fosaprepitant is effective for three-day cisplatin-based chemotherapy induced nausea and vomiting (CINV). We aim to explore the prophylactic antiemetic efficacy and safety of two doses of fosaprepitant included regimen in the patients receiving multiple-day cisplatin chemotherapy. Methods This randomized, parallel-group, open-labelled study was conducted in nine hospitals between February 2021 and February 2023. Patients diagnosed as lung cancer and chemotherapy naive were screened. Eligible participants were scheduled to be treated with highly emetogenic chemotherapy regimen which including three days of cisplatin. Then they were randomly divided into the experimental group (two doses of fosaprepitant, Group 2DF) and the control group (one dose of fosaprepitant, Group C). The primary endpoints included the safety and the average none CINV days (NCDs). This study was registered on the website of chictr.org.cn, number ChiCTR2100042665. Results Overall, 204 participants were randomly assigned, and 198 patients were analyzed. No statistical difference in adverse events was found between the two groups. All treatment-related adverse effects for fosaprepitant observed were of grade 1–2. The average NCDs of Group 2DF was significantly more than Group C (18.21 ± 3.40 days vs 16.14 ± 5.20 days, P = 0.001). Furthermore, the better life function score was achieved in Group 2DF according to FLIE questionnaire. Conclusion The administration of two-dose fosaprepitant was safe and more effective than one dose in protecting patients from CINV induced by three-day cisplatin included chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting

Li,

Wan,

Yang

et al. 2024

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…More than 60% of CINV can be effectively prevented if standardized prophylactic antiemetic treatments were given to patients according to the relevant guidelines ( 27 ). In addition, optimized anti-emetic protocols, such as Chinese herbal medicine, can be adopted to enhance the preventive efficacy ( 28 , 29 ). Based on the data of this study, adopting practical and effective prevention plans will greatly reduce the incidence of CINV in chemotherapy patients, which may reduce the risk of anxiety/depression among family caregivers.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy induced nausea and vomiting may cause anxiety and depression in the family caregivers of patients with cancer

Luo,

Yang,

Chen

et al. 2023

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

ObjectiveTo investigate the impact of chemotherapy induced nausea and vomiting (CINV) on the anxiety and depression of the primary family caregivers of patients with cancer.MethodsThis study screened family caregivers of patients with cancer undergoing highly emetogenic chemotherapy (HEC) containing a 3-day cisplatin regime. Caregivers who did not experience anxiety or depression at baseline screening were enrolled in this study. Based on the patients’ CINV status during chemotherapy, their family caregivers were divided into two groups: patients who experienced CINV (CINV group) and patients who did not experience CINV (No-CINV group). All enrolled family caregivers completed the Hospital Anxiety and Depression Scale (HADS) questionnaire on the fourth and 8 days of chemotherapy.ResultsA total of 256 family caregivers were screened for this study, of which 195 caregivers without anxiety or depression at baseline were included. A total of 150 (76.9%) patients undergoing chemotherapy experienced acute CINV; 63 (42%) of their family caregivers experienced anxiety, and 65 (43.3%) developed depression. This was significantly higher than the experiences of the No-CINV group (2.2%, P < 0.001; 0%, P < 0.001, respectively). Among the patients undergoing chemotherapy, 86 (44.1%) experienced delayed CINV. The incidence of anxiety and depression in the family caregivers of patients with delayed CINV were 27.9 and 36%, respectively, both of which were significantly higher than that in the family caregivers of the No-CINV group (0.9%, P < 0.001; and 0.9%, P < 0.001, respectively).ConclusionAcute and delayed CINV occurring in patients during chemotherapy may induce anxiety and depression in their family caregivers.

show abstract

Protective Effects of Huo Xiang Zheng Qi Liquid on Clostridioides difficile Infection on C57BL/6 Mice

Chen,

Zhai,

Schønning

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Background: Clostridioides difficile-associated disease (CDAD) is a major healthcare-associated infection. New treatment options for CDAD are needed. A traditional Chinese medicinal formula, Huo Xiang Zheng Qi (HXZQ), was chosen to test against CDAD in a mouse model. Methods: C57BL/6 mice were challenged with C difficile (ATCC 43255) orally; then received saline; vancomycin 25 mg/kg; or HXZQ in two different concentrations twice daily for 5 days. The animals’ body weight; clinical signs; and survival rates were registered daily. Fecal pellets from each animal were taken for PCR analysis as a control of infection. Results: 50% of the mice receiving saline died; 85.7% of the mice receiving vancomycin survived; 75% of the mice receiving HXZQ survived; and 87.5% of the mice receiving a 1:1 saline dilution of HXZQ survived. The HXZQ-treated groups were C. difficile PCR positive with loads less than that of the untreated mice. The weight loss in the vancomycin plus HXZQ 1:1 treated group; the vancomycin-treated group; and the untreated group were 3.08%, 4.06%, and 9.62%, respectively. Conclusions: our results showed that HXZQ can protect mice from CDAD-related death as effectively as vancomycin and the combination of vancomycin and HXZQ may give even better protection.

show abstract

Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial

Cited by 3 publications

References 21 publications

Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting

Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting

Chemotherapy induced nausea and vomiting may cause anxiety and depression in the family caregivers of patients with cancer

Protective Effects of Huo Xiang Zheng Qi Liquid on Clostridioides difficile Infection on C57BL/6 Mice

Contact Info

Product

Resources

About